These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 9222272)

  • 1. Attempts to obtain neuroprotection in Parkinson's disease.
    Olanow CW
    Neurology; 1997 Jul; 49(1 Suppl 1):S26-33. PubMed ID: 9222272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonists and neuroprotection in Parkinson's disease.
    Olanow CW; Jenner P; Brooks D
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S167-74. PubMed ID: 9749590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview.
    Stern MB
    Neurology; 1997 Jul; 49(1 Suppl 1):S2-9. PubMed ID: 9222270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of early Parkinson's disease.
    Hauser RA; Zesiewicz TA
    Med Clin North Am; 1999 Mar; 83(2):393-414, vi. PubMed ID: 10093585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection for Parkinson's disease.
    Koller WC
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S155-9. PubMed ID: 9749588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical importance of neuroprotection in Parkinson's disease.
    Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
    J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
    Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
    Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM
    Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in managing Parkinson's disease.
    Waters CH
    Hosp Pract (1995); 2001 Jun; 36(6):27-32, 41. PubMed ID: 11419534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 16. Free-radical toxicity and antioxidant medications in Parkinson's disease.
    Ciccone CD
    Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
    [No Abstract]   [Full Text] [Related]  

  • 17. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S; Heinonen EH; Hägglund J; Kaugesaar T; Kontants H; Mäki-Ikola O; Palm R; Turunen J
    Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2003 Dec; (10):1582-98. PubMed ID: 15555162
    [No Abstract]   [Full Text] [Related]  

  • 19. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 20. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
    Schneider E
    J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.